CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 44 enrolled
Drug / intervention
crenolanib +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02283177
NCT02283177Phase 2Completed
CompareCT.gov

A Safety and Tolerability Trial of Crenolanib and Chemotherapy With Cytarabine and Anthracyclines in Patients With Newly Diagnosed Acute Myeloid Leukemia With FLT3 Activating Mutations

Arog Pharmaceuticals, Inc.·interventional·Posted Nov 5, 2014·Updated Feb 2, 2024

In Brief

A Phase 2 clinical trial evaluating crenolanib, cytarabine, and 2 other interventions for Newly Diagnosed AML With FLT3 Activating Mutations. Completed, enrolled 44 participants across 9 sites.

Detailed Summary

This pilot study is designed to evaluate the safety and tolerability of oral crenolanib besylate given sequentially during standard induction and consolidation chemotherapy in patients with newly diagnosed AML with FLT3 activating mutations.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNewly Diagnosed AML With FLT3 Activating Mutations
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 5, 2014
Enrollment StartJan 1, 2015
Primary CompletionDec 1, 2019
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 11.7 years ago

Interventions

crenolanibdrug

cytarabinedrug

daunorubicindrug

idarubicindrug